Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Chao‑Yue Sun"'
Autor:
Chao-Yue Sun, Di Cao, Yue-Ning Wang, Nuo-Qing Weng, Qian-Nan Ren, Shuo-Cheng Wang, Mei-Yin Zhang, Shi-Juan Mai, Hui-Yun Wang
Publikováno v:
Cell Death and Disease, Vol 15, Iss 9, Pp 1-13 (2024)
Abstract Repositioning approved antitumor drugs for different cancers is a cost-effective approach. Gilteritinib was FDA-approved for the treatment of FLT3-mutated acute myeloid leukemia in 2018. However, the therapeutic effects and mechanism of Gilt
Externí odkaz:
https://doaj.org/article/14ecd2f3492b4731b12eed8508ce51a2
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment. However, several clinical trials demons
Externí odkaz:
https://doaj.org/article/35c47b2eb3044058a67bc323e15be05c
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
Unhealthy diet, in particular high-fat diet (HFD) intake, can cause the development of several metabolic disorders, including obesity, hyperlipidemia, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome
Externí odkaz:
https://doaj.org/article/f76dda8def524a069d04b63e0af0886d
Autor:
Chao-Yue Sun, Di Cao, Qian-Nan Ren, Shan-Shan Zhang, Ning-Ning Zhou, Shi-Juan Mai, Bing Feng, Hui-Yun Wang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Aberrant activation of the Ras–ERK signaling pathway drives many important cancer phenotypes, and several inhibitors targeting such pathways are under investigation and/or approved by the FDA as single- or multi-agent therapy for patients with mela
Externí odkaz:
https://doaj.org/article/8e9ad77372b94b5aaa84552061dbf2ee
Autor:
Juan Nie, Hong-Mei Yang, Chao-Yue Sun, Yan-Lu Liu, Jian-Yi Zhuo, Zhen-Biao Zhang, Xiao-Ping Lai, Zi-Ren Su, Yu-Cui Li
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Bleomycin (BLM) is a broad spectrum anti-tumor drug and inducing pulmonary fibrosis. As an anti-tumor drug without immunosuppression, it is urgent to find a drug that reduces the side effects of BLM. Scutellarin (SCU), a flavone extracted from Eriger
Externí odkaz:
https://doaj.org/article/061aa5cda0f74f38baec818ac7473992
Autor:
Chao-Yue Sun, Ying Zhu, Xiao-Feng Li, Xie-Qi Wang, Li-Peng Tang, Zu-Qing Su, Cai-Yun Li, Guang-Juan Zheng, Bing Feng
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Cisplatin, as the first-line anti-tumor agent, is widely used for treatment of a variety of malignancies including non-small cell lung cancer (NSCLC). However, the acquired resistance has been a major obstacle for the clinical application. Scutellari
Externí odkaz:
https://doaj.org/article/0ff5f4d886e94c55958675a163ddbecc
Publikováno v:
International Journal of Biological Sciences. 18:2744-2758
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85d48112967d5c981ec72ed9f564b09a
https://doi.org/10.7150/ijbs.70458
https://doi.org/10.7150/ijbs.70458
Publikováno v:
International Journal of Biological Sciences
Mammalian target of rapamycin (mTOR) is one of the most commonly activated pathways in human cancers, including lung cancer. Targeting mTOR with molecule inhibitors is considered as a useful therapeutic strategy. However, the results obtained from th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d014cc7fb2fc050bb48f7123bc7b95ea
http://europepmc.org/articles/PMC8375233
http://europepmc.org/articles/PMC8375233
Publikováno v:
Rare Metals. 41:1403-1405
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bec20ea57781f397dc1b8702ea1e473
https://doi.org/10.1007/s12598-021-01906-x
https://doi.org/10.1007/s12598-021-01906-x
Publikováno v:
Biomedicine & Pharmacotherapy. 161:114483
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c49601358f0d6a23206bdb64398f2b89
https://doi.org/10.1016/j.biopha.2023.114483
https://doi.org/10.1016/j.biopha.2023.114483